RxDoctor Payments Data

Kyle Cheng, MD

Dermatology · Burbank, CANPI 1306103064

Payments from drug & device makers

$19,987in general payments, 2019–2025

Across 205 payments — averaging $97.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$5K
  • UCB, Inc.$3K
  • AbbVie$2K
  • Johnson & Johnson$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Arcutis Biotherapeutics, Inc.$2K
  • plus $3K from 15 others

What the payments were for

  • Consulting fees$12,73564%
  • Food & beverage$6,71534%
  • Education$5373%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,987 in reported general payments places this provider in the 85th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$156,187
Medicare patients
535
Services billed
1,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa33$661,057
TremfyaGuselkumab42$565,365
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5015$454,805
Dupixent PenDupilumab76$282,071
Taltz AutoinjectorIxekizumab21$172,847
OtezlaApremilast26$156,044
OpzeluraRuxolitinib Phosphate14$26,759
ZoryveRoflumilast28$24,668
Tacrolimus45$7,449
Clobetasol Propionate65$5,216
Fluocinonide74$3,186
Calcipotriene18$2,943
Fluorouracil30$2,138
Timolol Maleate65$1,817
Ketoconazole109$1,652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,396$565,36542 claims
AmgenOtezla$29$156,04426 claims
Incyte CorporationOpzelura$216$26,75914 claims
Arcutis Biotherapeutics, Inc.Zoryve$2,168$24,66828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,875 dermatology providers in California.

Other dermatology in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →